Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Pevarello

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Future Medicinal Chemistry|March 24, 2011
Recent drug approvals from the US FDA and EMEA: what the future holdsPaolo Pevarello
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2005
An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexesAnna Vulpetti, Paolo Pevarello
Pharmaceutical Patent Analyst|November 19, 2013
Kinase inhibitors for CNS diseases: an analysis of the recent patent literatureFederica Amigoni, Elena Legnaghi, Paolo Pevarello
Trends in Pharmacological Sciences|December 7, 2007
CDK inhibitors in cancer therapy: what is next?Marcos Malumbres, Paolo Pevarello, Mariano Barbacid, et al.
Future Medicinal Chemistry|March 24, 2011
Ion channel blockers for the treatment of neuropathic painElena Colombo, Simona Francisconi, Laura Faravelli, et al.
Magnetic Resonance in Chemistry : MRC|July 1, 2010
Differentiation between [1,2,4]triazolo[1,5-a] pyrimidine and [1,2,4]triazolo[4,3-a]-pyrimidine regioisomers by 1H-15N HMBC experimentsAntonio Salgado, Carmen Varela, Ana María García Collazo, et al.
Journal of Medicinal Chemistry|May 31, 2002
NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligandsClaudio Dalvit, Marina Fasolini, Maria Flocco, et al.
Journal of Molecular Graphics & Modelling|November 2, 2005
Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitorsAnna Vulpetti, Elena Casale, Fulvia Roletto, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2006
A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitorMarcella Nesi, Daniela Borghi, Maria Gabriella Brasca, et al.
Pharmaceutical Patent Analyst|March 5, 2014
Ca(2+) release-activated Ca(2+) channel inhibitorsPaolo Pevarello, Silvia Cainarca, Chiara Liberati, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Future Medicinal Chemistry|March 24, 2011
Recent drug approvals from the US FDA and EMEA: what the future holdsPaolo Pevarello
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2005
An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexesAnna Vulpetti, Paolo Pevarello
Pharmaceutical Patent Analyst|November 19, 2013
Kinase inhibitors for CNS diseases: an analysis of the recent patent literatureFederica Amigoni, Elena Legnaghi, Paolo Pevarello
Trends in Pharmacological Sciences|December 7, 2007
CDK inhibitors in cancer therapy: what is next?Marcos Malumbres, Paolo Pevarello, Mariano Barbacid, et al.
Future Medicinal Chemistry|March 24, 2011
Ion channel blockers for the treatment of neuropathic painElena Colombo, Simona Francisconi, Laura Faravelli, et al.
Magnetic Resonance in Chemistry : MRC|July 1, 2010
Differentiation between [1,2,4]triazolo[1,5-a] pyrimidine and [1,2,4]triazolo[4,3-a]-pyrimidine regioisomers by 1H-15N HMBC experimentsAntonio Salgado, Carmen Varela, Ana María García Collazo, et al.
Journal of Medicinal Chemistry|May 31, 2002
NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligandsClaudio Dalvit, Marina Fasolini, Maria Flocco, et al.
Journal of Molecular Graphics & Modelling|November 2, 2005
Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitorsAnna Vulpetti, Elena Casale, Fulvia Roletto, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2006
A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitorMarcella Nesi, Daniela Borghi, Maria Gabriella Brasca, et al.
Pharmaceutical Patent Analyst|March 5, 2014
Ca(2+) release-activated Ca(2+) channel inhibitorsPaolo Pevarello, Silvia Cainarca, Chiara Liberati, et al.
Pageof 3